FDA Approved: ILEVRO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for ILEVRO (nepafenac) from Novartis Pharmaceuticals, expanding the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation Following Cataract Surgery
• Postoperative Ocular Pain

Drugs mentioned

• ILEVRO (nepafenac)

Snippet

SUPPL AP for ILEVRO (NEPAFENAC)